Atezolizumab to remain licensed in US for metastatic PD-L1 positive triple-negative breast cancer following updated review

Accelerated approval was previously granted on the basis of the results of the ImPassion130 study. Ongoing approval was granted despite the confirmatory IMPassion131 study failing to meet its primary endpoint of progression free survival when given as first line treatment.

Source:

Biospace Inc.